Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Qianqian Zhao
CONTACT
Lead
Shanghai Zhongshan Hospital
Second-line regimen with or without consolidative radiotherapy in patients with oligometastatic/locally advanced unresectable intrahepatic cholangiocarcinoma: an open-label, randomised, controlled study. Eligible patients will be randomized in a 1:1 ratio to receive either second-line regimen alone (control arm) or second-line regimen plus consolidative radiotherapy to all sites of known disease (investigational arm). patients in both arms have the option of receiving upfront or subsequent standard palliative radiotherapy to any symptomatic sites requiring prompt intervention. Because of the different treatment modalities in the study, it is not possible to blind the patient or physician to the treatment arm. Follow-up for tumor assessment will conclude 52 weeks after randomization.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
